Core Insights - Revolution Medicines (RVMD) reported a Q4 2025 loss of $1.86 per share, which is wider than the Zacks Consensus Estimate of a loss of $1.56, and a significant increase from a loss of $1.12 in the same quarter last year [1][7] - The company has no approved products and did not generate any revenues in 2025 [5][8] - RVMD's stock fell 5% in after-market trading following the earnings report, despite a year-to-date increase of 30%, outperforming the industry growth of 10% [1][2] Financial Performance - Research and development expenses for Q4 2025 were $294.9 million, reflecting a nearly 57% year-over-year increase, driven by higher costs for clinical studies and manufacturing [3] - General and administrative expenses reached $66.7 million, up more than 136% year-over-year, primarily due to increased commercial preparation activities and employee-related expenses [3] - For the full year 2025, the company reported a loss of $5.95 per share, wider than the $3.58 loss from the previous year [8] Cash Position - As of December 31, 2025, Revolution Medicines had cash and cash equivalents of $2 billion, an increase from $1.9 billion as of September 30, 2025 [4] 2026 Guidance - RVMD expects operating expenses for 2026 to be between $1.6 billion and $1.7 billion, which includes non-cash stock-based compensation expenses of $180-$200 million [9] Pipeline Developments - The company is advancing daraxonrasib, an investigational oral RAS(ON) multi-selective inhibitor, into multiple late-stage studies for pancreatic ductal adenocarcinoma (PDAC) and non-small cell lung cancer (NSCLC) [10][12] - The RASolute 302 study is assessing daraxonrasib in second-line metastatic PDAC, while the RASolute 303 study is evaluating its efficacy in the first-line setting [11] - RVMD has initiated the phase III RASolute 305 study to evaluate the combination of zoldonrasib with chemotherapy in first-line PDAC patients [14] Strategic Collaborations - To enhance its pipeline, Revolution Medicines has entered into collaborations with companies like Summit Therapeutics and Tango Therapeutics to evaluate combinations of its RAS(ON) inhibitors with their drugs [15] - A recent collaboration with Bristol Myers Squibb aims to evaluate daraxonrasib in combination with navlimetostat for certain pancreatic cancer patients [16]